Myungin Pharm명인제약
317450 · KOSPI · ₩317450 · 명인제약
₩40,100▲ ₩400 (1.01%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Revenue | ₩76B | ₩72B | ₩72B |
| Cost of sales | ₩28B | ₩28B | ₩28B |
| Gross profit | ₩48B | ₩45B | ₩44B |
| Operating income | ₩28B | ₩25B | ₩24B |
| Net income | ₩24B | ₩23B | ₩23B |
| Net income to shareholders | ₩24B | ₩23B | ₩23B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Total assets | ₩868B | ₩871B | ₩842B |
| Current assets | ₩620B | ₩657B | ₩643B |
| Cash and equivalents | ₩27B | ₩38B | ₩32B |
| Total liabilities | ₩52B | ₩76B | ₩47B |
| Current liabilities | ₩50B | ₩74B | ₩46B |
| Total equity | ₩816B | ₩794B | ₩794B |
| Shareholders' equity | ₩816B | ₩794B | ₩794B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Cash from operations | ₩9.8B | ₩30B | ₩24B |
| Capital spending | ₩15B | ₩12B | ₩10B |
| Free cash flow | −₩5.1B | ₩18B | ₩13B |
| Dividends paid | ₩0 | ₩22B | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Myungin Pharm / 명인제약 / 317450 / KRX:317450
Source: KRX statistical information